Glenmark sees innovative drugs taking bigger revenue share
In short
Glenmark Pharmaceuticals says innovative drugs will make up a bigger share of its revenue. CMD Glenn Saldanha said the company is moving beyond generics.
This could change Glenmark’s business mix and future earnings, but the reporting does not say which drugs will lead the shift or when it will happen.
What the reporting says
Glenmark Pharmaceuticals expects innovative drugs to contribute a higher share of revenue as it shifts focus beyond generics, CMD Glenn Saldanha said. The reporting does not give a target revenue mix, timeframe, or specific products. The immediate implication is a strategic tilt toward higher-value medicines, but the pace and financial effect are not stated.
Why it matters
Glenmark Pharmaceuticals said innovative drugs should account for a higher share of revenue as it moves beyond generics. That suggests a strategy shift toward higher-value products, which could affect margins and growth if the pipeline performs. The source does not name specific drugs, targets, or timing, so the scale of the change is unclear.